2006 12 Clinical Trials in Emerging Markets

Information about 2006 12 Clinical Trials in Emerging Markets

Published on April 7, 2008

Author: Prudenza

Source: authorstream.com

Content

Clinical Trials in Emerging Markets C5’s Forum on Ensuring Compliance & Managing Legal Risks in Structuring & Conducting Clinical Trials, December 2006, London :  Clinical Trials in Emerging Markets C5’s Forum on Ensuring Compliance & Managing Legal Risks in Structuring & Conducting Clinical Trials, December 2006, London Nermeen Varawalla, MD, DPhil (Oxon), MBA Vice President, Corporate Development PRA International Agenda: Clinical Trials in Emerging Markets:  Agenda: Clinical Trials in Emerging Markets Value Proposition Trial Execution Addressing Concerns Looking Ahead Emerging Markets of Clinical Development:  Mexico Brazil Argentina Chile Poland Russia Hungary Other CEEC South Africa Australia & New Zealand China South East Asia India Emerging Markets of Clinical Development Although at different stages of maturity, member countries are remarkably similar. Emerging World Clinical Development: the Balancing Act:  Emerging World Clinical Development: the Balancing Act Nascent clinical development environments Prolonged regulatory processes Relatively poor commercialisation potential Ethical dilemmas Concerns regarding Intellectual Property protection Large patient populations with diseases of both developed and developing world Fewer competitor trials Motivated investigators Potential for cost savings High growth markets of tomorrow Attractions Challenges Cancer Patients in India:  Cancer Patients in India About 3 million diagnosed cases 850,000 new cases every year (1 million in USA) 50%+ of cancer cases: oral cavity, lung and cervix Other common cancers: breast, head & neck, and pancreas Potentially much higher true cancer caseload The speed of patient recruitment for oncology clinical trials in India is up to seven times faster than in the United States. Speedy Recruitment for Oncology Studies in Central and Eastern Europe :  Speedy Recruitment for Oncology Studies in Central and Eastern Europe PRA Experience – 2003 in Poland, Hungary, Czech Republic & Slovakia Patient Recruitment can be up to 10 times Faster than in the US.:  Patient Recruitment can be up to 10 times Faster than in the US. Breast Cancer, Phase III, PRA Study Cumulative Enrolment by Country (N=723 Patients) 20 patients / site 10 Sites 15 Sites 15 Sites 200 Sites 0 50 100 150 200 250 300 Poland Russia Mexico USA Enhanced Site Effectiveness (pts/site) in Emerging Countries:  Enhanced Site Effectiveness (pts/site) in Emerging Countries Asia-Pacific South-Central America CE Europe Western Europe United States Pts / site Source: Sponsor Experience 2001 - 2005 Fewer Ineffective Sites in Emerging Countries :  Fewer Ineffective Sites in Emerging Countries Asia-Pacific South-Central America CE Europe Western Europe United States Source: Sponsor Experience 2001 - 2005 % of sites with 0-1 pts Slide10:  0 5 10 15 20 25 30 Estonia Hungary Lithuania Poland Russia Austria Belgium France Germany Italy Spain Sweden Holland UK No of Sites Patient/Site Comparison of Site Performance across Europe Queries/Pt Source: PRA Experience 2002 - 2005 Slide11:  Source: Freedom of Information FDA, 2005 Findings of FDA Inspections % Slide12:  Source: Freedom of Information FDA, 2005 Outcomes of FDA Inspections % Clinical Study Cost Comparisons by Country:  Clinical Study Cost Comparisons by Country 0.72 1.09 0.71 1.56 0.93 1 0.42 0.4 0.52 0.56 Poland UK France Germany Spain US Australia Russia China India Source: FastTrack Systems Global Cost Databases, 2006 Cost Savings from utilising Emerging Countries can be Substantial:  Cost Savings from utilising Emerging Countries can be Substantial Treatment costs 30% of those in the US Lower costs for medication, investigations and hospitalisation Reduced and cheaper domestic travel Urban concentration of sites Cheaper fares & tariffs Support Services Printing, translation, local courier Data Management Variability of Clinical Grants (USD) :  Variability of Clinical Grants (USD) 0 2000 4000 6000 8000 10000 12000 14000 Netherlands USA Germany Australia Canada Mexico Argentina Peru Poland Brazil Russia Source: FastTrack Systems Global Cost Databases, 2006 Correlation of Data Quality with Clinical Grants. :  Correlation of Data Quality with Clinical Grants. Clinical Grant USD/pt No of queries / 100 CRF pages 8.6 11.1 12.5 8.4 22.7 13.6 15.0 18.5 12.0 9.0 8.9 0 5000 10000 15000 Netherlands USA Germany Australia Canada Mexico Argentina Peru Poland Brazil Russia 0 4 8 12 16 20 24 Source: FastTrack Systems Global Cost Databases, 2006 Key Advantages of Emerging Markets :  Key Advantages of Emerging Markets    Emerging Countries have Future Commercial Value: China Example:  Emerging Countries have Future Commercial Value: China Example 0 5 10 15 20 25 2004 2005 2010 Pharmaceutical Market Size in USD Billion 7th largest pharmaceutical market in the world in revenue Rapid growth fuelled by: Population = 1.33 bn in 2005 60 yr olds = 160 M in 2005, 280 M in 2025 Relatively low baseline: per capita drug expenditure at 12 USD is 2% of that in the US Urbanisation & affluence Conversion from the exclusive use of Traditional Chinese Medicine Most large pharmaceutical companies have a major presence in China Regulatory Approval Times:  Regulatory Approval Times 0 30 90 270 China Brazil India Czech Republic Poland Australia / NZ South Africa Russia Taiwan Korea Hong Kong Singapore US Days Trend is for regulatory approval timelines to further decrease Uncertainty around approval times is reducing Countries have processes with clear instructions for documentation Local knowledge and liaison with regulator is essential Slow Regulatory Process in China:  Slow Regulatory Process in China State Food and Drug Administration (SFDA) Application acceptance Notification for drug specifications validation & verification Centre for Drug Evaluation (CDE) Technical review National Institute for the Control of Pharmaceutical & Biological Product (NICPBP) Drug specifications validation & verification Additional information / revisions requested Single collated submissions within 4 months CDE reviews supplemental submission Application SFDA final review Clinical trial approval Protocol, ICF, EC approval Study sites & investigators submitted & filed with SFDA before study start Approval refused - 85 days - - 20 days - - 120 days - - 40 days - - 20 days - Slide21:  Countries like Korea have Streamlined their Regulatory Approvals. Slide22:  Healthcare Systems in Emerging Countries Conducive for Clinical Research Private Private Pharmacies Private Hospitals Private Outpatient Centers Dentistry Ophthalmologists Gynecologists Dermatologists Pharmacies Pediatricians GPs Psychiatry Suited for global clinical trials in hospital based populations Asia offers a Wide Choice of Investigative Sites. :  Asia offers a Wide Choice of Investigative Sites. INDIA CHINA East ASIA Queen Mary University Hospital, Hongkong with 1400 beds serves a population of 1.5 million people Singapore’s National University Hospital - a 930 bedded acute and specialist hospital Veteran’s General Hospital, Taipei, Taiwan has 440 specialists, 300 beds, 2.5 M patients attend out patients clinics and 1 M receive in patient care per year The National Taiwan University Hospital has 4,000 staff serves approximately 0.6 M inpatients and 2.4M outpatients per year Renji Hospital, Pudong Shanghai has 1,000 beds & 2,300 staff Ruijin Hospital, Shanghai has 1,385 beds & 3,242 staff Peking Union Medical College Hospital is upgrading to better serve international sponsors Asian Clinical Trial Networkcovers Korea, Malaysia, Thailand, Vietnam and Taiwan. Tata Memorial Hospital, Mumbai— ideal for Oncology Studies:  Tata Memorial Hospital, Mumbai— ideal for Oncology Studies 25,000 cancer patients visit each yr from India & neighboring countries 1,000 patients attend out-patient clinics each day 441 in-patient beds 10,000 major operations each yr 5,000 radiotherapy & chemotherapy treatments delivered each yr Equipped with spiral CT scanner, gamma cameras, linear accelerator, bone marrow transplant facilities etc. Clinical Research Secretariat to coordinate clinical trials Satellite hospital with beds assigned for clinical trial participants Smart Design of Global Clinical Trials:  Smart Design of Global Clinical Trials Divide patient enrolment between North America, Western Europe & Emerging Countries Include 3-4 Emerging Countries Plan for enough sites & patients / region to make it worthwhile Utilise study start up time to identify investigators & subjects Confirm protocol feasibility Ensure access to capabilities Obtain a US IND & initiate US sites first Perform the vast majority of global data management in India Obtain quality data to meet FDA / MHRA requirements Reduce patient recruitment times Address commercial imperatives Mitigate risk Capture efficiencies Goals Actions India—Compelling for Data Management:  India—Compelling for Data Management Large and growing resource pool Highly developed process innovation skills Credible data quality Operational flexibility to manage “crunch” periods Cost-effectiveness Software options Established data management software e.g. Oracle Clinical, Clintrial, PRA Flex DMS™ Range of services available Data entry & verification Statistical analysis, medical writing, software programming The case for off-shoring global data management to India Addressing Sponsors’ Concerns:  Addressing Sponsors’ Concerns Regulatory approval process more streamlined & predictable Study start-up up to 12 weeks from regulatory submission Regulatory approval timelines need to further decrease Government / industry initiatives to strengthen ethics committee approval processes Recognition of critical importance of informed consent Overall benefit to healthcare delivery in Emerging Countries Data for pivotal studies accepted by the FDA / EMEA Successful FDA audits Investment in education & training: state & private Quality Regulatory Approvals Ethics Apparent commitment to uphold and enforce Intellectual Property protection as per international standards IP Protection Benefits for Healthcare Delivery in Emerging Countries. :  Benefits for Healthcare Delivery in Emerging Countries. Treatment arm study participants access biomedical innovation All participants enjoy improved care Injection of resources into local healthcare system Standards of medical practice improve: communication, record keeping, evidence based medicine Not exploitation! – provided ICH GCP standards are followed: informed consent, expanded access Concerns about functioning of Ethics Committees are being addressed:  Concerns about functioning of Ethics Committees are being addressed Local Ethics Committee exist in > 200 clinical centres ICMR (Indian Council for Medical Research) to review & audit the functioning of ECs introduce a national accreditation system for ECs develop the Independent Forum for Ethics Review Committees, a training body Revised Schedule Y of Drugs and Cosmetics Act governing clinical trial conduct has prescribed roles and responsibilities of ECs composition as per ICH GCP guidelines formats for the EC approval letter provisions for inspection The India Example Changing Mix of FDA-Regulated Clinical Investigators:  Changing Mix of FDA-Regulated Clinical Investigators % of total 1572s filed Source: Tufts CSDD Building & Nurturing Investigator Networks :  Building & Nurturing Investigator Networks Recognizing critical importance Patient Access Data Quality Ethical Integrity Growing the Investigator Pool Proactive acquisition Training Nurturing Investigator Networks Ongoing training / education “Respectful” feasibility Site level support Investigator & Site Relationship Management Slide32:  Mexico Brazil Argentina Chile Poland Russia Hungary Other CEEC South Africa Australia & New Zealand China India Requirements to Unlock the Clinical Trial opportunities in Emerging Countries. Thorough knowledge of local regulatory processes & operations Deep relationships with local physicians and medical centres Expertise in clinical development for FDA / MHRA Local application of global processes & systems Questions…..:  Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA Vice President Corporate Development, PRA International Pacific House Imperial Way, Worton Grange Reading, Berkshire RG2 OTD, UK Tel: +44 7900 227783 E-mail: [email protected] Website: www.prainternational.com 6th floor Sterling Center Dr Annie Besant Road, Mumbai 400 018, INDIA Questions…..

Related presentations


Other presentations created by Prudenza

chapter8 2005
16. 01. 2008
0 views

chapter8 2005

wk10 Satellite Microwave
24. 03. 2008
0 views

wk10 Satellite Microwave

ReidPresentation
22. 01. 2008
0 views

ReidPresentation

Job Hazard Analysis
08. 01. 2008
0 views

Job Hazard Analysis

physics121 lecture02
09. 01. 2008
0 views

physics121 lecture02

Research powerpoint for proverbs
10. 01. 2008
0 views

Research powerpoint for proverbs

FlightInstruments
13. 01. 2008
0 views

FlightInstruments

eacl2003ws ryu i
14. 01. 2008
0 views

eacl2003ws ryu i

coup de chaleur SFAR
15. 01. 2008
0 views

coup de chaleur SFAR

ab regions
15. 01. 2008
0 views

ab regions

l5
17. 01. 2008
0 views

l5

icebreaking games
17. 01. 2008
0 views

icebreaking games

ringsandmoons
17. 01. 2008
0 views

ringsandmoons

d000381
20. 01. 2008
0 views

d000381

vis2006present v4
21. 01. 2008
0 views

vis2006present v4

Media Planning for ISC
23. 01. 2008
0 views

Media Planning for ISC

spatical data mining 20040909
24. 01. 2008
0 views

spatical data mining 20040909

Victorian Wedding Food
05. 02. 2008
0 views

Victorian Wedding Food

icebear w300
05. 02. 2008
0 views

icebear w300

068229 Ch06 slides
06. 02. 2008
0 views

068229 Ch06 slides

Presentation1 weather
12. 02. 2008
0 views

Presentation1 weather

insurv
08. 01. 2008
0 views

insurv

Structural Change L 10
28. 01. 2008
0 views

Structural Change L 10

Cellphones on campus
31. 01. 2008
0 views

Cellphones on campus

lesson3
07. 02. 2008
0 views

lesson3

bits rit
07. 02. 2008
0 views

bits rit

taxonomy
14. 02. 2008
0 views

taxonomy

2003WIPP
09. 01. 2008
0 views

2003WIPP

LBO 2007 brief
24. 01. 2008
0 views

LBO 2007 brief

03 java program
09. 01. 2008
0 views

03 java program

CitingSources
28. 01. 2008
0 views

CitingSources

acts
25. 02. 2008
0 views

acts

wp3
28. 02. 2008
0 views

wp3

enterobac05
21. 02. 2008
0 views

enterobac05

Iraq
03. 03. 2008
0 views

Iraq

2006 Budget presentation to NCAI
05. 03. 2008
0 views

2006 Budget presentation to NCAI

Federalism
14. 03. 2008
0 views

Federalism

Balloon Spacecraft
16. 01. 2008
0 views

Balloon Spacecraft

BECAS PRESENTACION
03. 04. 2008
0 views

BECAS PRESENTACION

Mervyn
15. 02. 2008
0 views

Mervyn

HACS
08. 04. 2008
0 views

HACS

SolitaryPulmonaryNod ule
06. 02. 2008
0 views

SolitaryPulmonaryNod ule

Hawaii Presentation 2008
08. 03. 2008
0 views

Hawaii Presentation 2008

200507am
29. 01. 2008
0 views

200507am

Major constellations
12. 02. 2008
0 views

Major constellations

GW05 XACMLandGlobus Demo
11. 01. 2008
0 views

GW05 XACMLandGlobus Demo

NASAProgram
22. 01. 2008
0 views

NASAProgram

OleMiss
12. 01. 2008
0 views

OleMiss

African American Song
16. 01. 2008
0 views

African American Song

plummer
20. 02. 2008
0 views

plummer

117
22. 01. 2008
0 views

117

CSDKhanGujurattalk
23. 01. 2008
0 views

CSDKhanGujurattalk

Campus Security Authorities
29. 02. 2008
0 views

Campus Security Authorities